Skip to main content

Direction about advertisements: Mr David Leyonhjelm

Direction under Section 42DV
Mr Leyonhjelm was directed to cease advertising a prescription medicine for the treatment of Covid-19.
Published

Help us improve the Therapeutic Goods Administration site